The anti-CD30 antibody-drug conjugate brentuximab vedotin is effective in anaplastic large cell lymphoma [9], however, CD30 is not typically expressed in γδ cancers [2]. The gene discussed is TNFRSF8; the disease is anaplastic large cell lymphoma.